Related Experiment Video

Updated: May 2, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.0K

Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review

Thao Nguyen1, Jashin J Wu2

  • 1Dermatologist at the Los Angeles Medical Center in CA. thao.u.nguyen@kp.org.

The Permanente Journal
|March 15, 2014
PubMed

Insights

Tumor necrosis factor-α inhibitors may reduce cardiovascular risk in psoriasis patients by lowering systemic inflammation. Further research is needed to confirm these benefits for major adverse cardiac events.

Area of Science:

  • Dermatology
  • Cardiology
  • Immunology

Background:

  • Psoriasis is a skin condition linked to systemic inflammation and increased cardiovascular disease (CVD) risk.
  • Tumor necrosis factor-α (TNF-α) inhibitors are used to treat psoriasis.
  • TNF-α inhibitors have been associated with reduced major adverse cardiac events (MACE) in psoriasis patients, but mechanisms are unclear.

Purpose of the Study:

  • To review evidence supporting the cardiovascular benefits of TNF-α inhibitors in psoriasis.
  • To explore potential mechanisms by which TNF-α inhibitors may lower cardiovascular risk.

Main Methods:

  • Review of existing scientific literature and clinical studies.
  • Analysis of data on TNF-α inhibitor use and cardiovascular outcomes in psoriasis patients.

Main Results:

  • Evidence suggests TNF-α inhibitors may offer cardiovascular protection in psoriasis.
  • Potential mechanisms include reducing systemic inflammation and improving cardiovascular risk factors.

Conclusions:

  • TNF-α inhibitors show promise in mitigating cardiovascular risk associated with psoriasis.
  • Larger studies are required to definitively quantify the risk reduction of biologic agents on MACE.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
34
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741